Fengping Shan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fengping Shan has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Noreen Griffin
Biostax Inc. 1317 Edgewater Dr., Ste 4882, Orlando, FL 32804, USA
18 shared publicationsYiming Meng
Central Laboratory, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Institute and Hospital), No. 44, Xiaoheyan Road, Shenyang 110042, Liaoning Province, China
13 shared publicationsNa Qu
Department of Gynecological Radiotherapy Ward, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Institute and Hospital), No. 44, Xiaoheyan Road, Shenyang 110042, Liaoning Province, China
8 shared publicationsXiaonan Wang
Department of Immunology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning Province 110122, China
8 shared publicationsNing Liu
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China
7 shared publicationsXinghua Gao
Department of Dermatology, No. 1 Teaching Hospital, China Medical University, Shenyang, 110016, China
7 shared publications
Latest Publications
- 28 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112734
Corrigendum to “Methionine enkephalin inhibited cervical cancer migration as well as invasion and activated CD11b+ NCR1+ NKs of tumor microenvironment” [Int. Immunopharmacol. 124(Pt B) (2023) 110967. doi: 10.1016/j.intimp.2023.110967. Epub 2023 Sep 21.]
- 28 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112734
Corrigendum to “Methionine enkephalin inhibited cervical cancer migration as well as invasion and activated CD11b+ NCR1+ NKs of tumor microenvironment” [Int. Immunopharmacol. 124(Pt B) (2023) 110967. doi: 10.1016/j.intimp.2023.110967. Epub 2023 Sep 21.]
- 15 November 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt B) , 111226
In vitro and in vivo killing effects of methionine enkephalin on osteosarcoma
- 15 November 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt B) , 111226
In vitro and in vivo killing effects of methionine enkephalin on osteosarcoma
- Open Access
- 12 October 2023
- Published by Springer Nature in BMC Immunology
- Vol. 24 (1) , 1-11
Methionine enkephalin(MENK) upregulated memory T cells in anti-influenza response
Novel prophylactic drugs and vaccination strategies for protection against influenza virus should induce specific effector T-cell immune responses in pulmonary airways and peripheral lymphoid organs. Designing approaches that promote T-cell-mediated responses and memory T-cell differentiation would strengthen host resistance to respiratory infectious diseases. The results of this study showed that pulmonary delivery of MENK via intranasal administration reduced viral titres, upregulated opioid receptor MOR and DOR, increased the proportions of T-cell subsets including CD8+ T cells, CD8+ TEM cells, NP/PA-effector CD8+ TEM cells in bronchoalveolar lavage fluid and lungs, and CD4+/CD8+ TCM cells in lymph nodes to protect mice against influenza viral challenge. Furthermore, we demonstrated that, on the 10th day of infection, the proportions of CD4+ TM and CD8+ TM cells were significantly increased, which meant that a stable TCM and TEM lineage was established in the early stage of influenza infection. Collectively, our data suggested that MENK administered intranasally, similar to the route of natural infection by influenza A virus, could exert antiviral activity through upregulating T-cell-mediated adaptive immune responses against influenza virus.
- 12 October 2023
- Published by Springer Nature in BMC Immunology
- Vol. 24 (1) , 1-11
Open AccessMethionine enkephalin(MENK) upregulated memory T cells in anti-influenza response
Novel prophylactic drugs and vaccination strategies for protection against influenza virus should induce specific effector T-cell immune responses in pulmonary airways and peripheral lymphoid organs. Designing approaches that promote T-cell-mediated responses and memory T-cell differentiation would strengthen host resistance to respiratory infectious diseases. The results of this study showed that pulmonary delivery of MENK via intranasal administration reduced viral titres, upregulated opioid receptor MOR and DOR, increased the proportions of T-cell subsets including CD8+ T cells, CD8+ TEM cells, NP/PA-effector CD8+ TEM cells in bronchoalveolar lavage fluid and lungs, and CD4+/CD8+ TCM cells in lymph nodes to protect mice against influenza viral challenge. Furthermore, we demonstrated that, on the 10th day of infection, the proportions of CD4+ TM and CD8+ TM cells were significantly increased, which meant that a stable TCM and TEM lineage was established in the early stage of influenza infection. Collectively, our data suggested that MENK administered intranasally, similar to the route of natural infection by influenza A virus, could exert antiviral activity through upregulating T-cell-mediated adaptive immune responses against influenza virus.
- 20 September 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt B) , 110967
Methionine enkephalin inhibited cervical cancer migration as well as invasion and activated CD11b+ NCR1+ NKs of tumor microenvironment
- 20 September 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt B) , 110967
Methionine enkephalin inhibited cervical cancer migration as well as invasion and activated CD11b+ NCR1+ NKs of tumor microenvironment
- 18 August 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 111, 109125
Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment
- 18 August 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 111, 109125
Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment
- 20 June 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 110, 108933
Methionine enkephalin inhibited cervical carcinoma via apoptosis promotion and reduction of myeloid derived suppressor cell infiltrated in tumor
- 20 June 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 110, 108933
Methionine enkephalin inhibited cervical carcinoma via apoptosis promotion and reduction of myeloid derived suppressor cell infiltrated in tumor
- 24 May 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 108, 108881
Interleukin-10 family members: Biology and role in the bone and joint diseases
- 24 May 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 108, 108881
Interleukin-10 family members: Biology and role in the bone and joint diseases
- 1 February 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 103, 108484
PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
- 1 February 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 103, 108484
PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
- 1 October 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 99, 107713
Research progress of opioid growth factor in immune-related diseases and cancer diseases
- 1 October 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 99, 107713
Research progress of opioid growth factor in immune-related diseases and cancer diseases